← Leaderboards
Meredith Bond
Cleveland Clinic Foundation
$7,705,624
Attributed
$8,181,155
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $972.3K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,181,155 · 6
By mechanism
R01$5,996,418 · 3
T32$1,849,442 · 2
R21$335,295 · 1
Top collaborators
- Christine S Moravec5 shared
Others in their field
Top investigators on “Phosphorylation”
- Paul S. Aisen · Cognition Therapeutics, Inc.$88,828,963
- Alan F Horwitz · University Of Virginia Charlottesville$38,916,638
- Tony R. Hunter · Salk Institute For Biological Studies$34,955,666
- Adam L Boxer · Mayo Clinic Rochester$31,930,809
- Keith A. Johnson · Banner Health$30,350,302
- Paul Greengard · Rockefeller University$28,632,392
Research focus
PhosphorylationHeart FailureA Kinase Anchoring ProteinHuman TissueCardiacEnzyme ActivityLaboratory RatProtein Kinase ASurface Plasmon ResonanceHeartComplexResponsePathway InteractionsAgingCyclic Amp-Dependent Protein KinasesAffinityBinding (Molecular Function)RattusRegulationBinding ProteinsGene TransferMicrofilamentsProtein KinaseIn Vivo
Grant awards (33)
CD-Cavs: Cross-Disciplinary Cardiovascular Sciences Training Program to Diversify the STEM workforce$193,198
T32 · FY2024 · HL · contact PI
CD-Cavs: Cross-Disciplinary Cardiovascular Sciences Training Program to Diversify the STEM workforce$233,723
T32 · FY2023 · HL · contact PI
CD-Cavs: Cross-Disciplinary Cardiovascular Sciences Training Program to Diversify the STEM workforce$228,636
T32 · FY2022 · HL · contact PI
CD-Cavs: Cross-Disciplinary Cardiovascular Sciences Training Program to Diversify the STEM workforce$169,816
T32 · FY2021 · HL · contact PI
CD-Cavs: Cross-Disciplinary Cardiovascular Sciences Training Program to Diversify the STEM workforce$125,690
T32 · FY2020 · HL · contact PI
Training Grant in Cardiac and Vascular Cell Biology$357,686
T32 · FY2010 · HL · contact PI
Training Grant in Cardiac and Vascular Cell Biology$344,597
T32 · FY2009 · HL · contact PI
AKAP Regulation of PKA Targeting in the Heart$283,069
R01 · FY2009 · AG · contact PI
AKAP Regulation of PKA Targeting in the Heart$276,723
R01 · FY2009 · AG · contact PI
AKAP Regulation of PKA Targeting in the Heart$335,611
R01 · FY2008 · AG · contact PI
Synemin is an A-Kinase Anchoring Protein in the Heart$331,685
R01 · FY2008 · HL · contact PI
Predicting Heart Failure: Gene Profiling of Amplified RNA From Human Biopsies$181,545
R21 · FY2008 · AG · contact PI
AKAP Regulation of PKA Targeting in the Heart$51,054
R01 · FY2008 · AG · contact PI
Synemin is an A-Kinase Anchoring Protein in the Heart$332,277
R01 · FY2007 · HL · contact PI
AKAP Regulation of PKA Targeting in the Heart$290,207
R01 · FY2007 · AG · contact PI
Training Grant in Cardiac and Vascular Cell Biology$196,096
T32 · FY2007 · HL · contact PI
Predicting Heart Failure: Gene Profiling of Amplified RNA From Human Biopsies$153,750
R21 · FY2007 · AG · contact PI
Synemin is an A-Kinase Anchoring Protein in the Heart$342,793
R01 · FY2006 · HL · contact PI
AKAP Regulation of PKA Targeting in the Heart$299,495
R01 · FY2006 · AG · contact PI
Synemin is an A-Kinase Anchoring Protein in the Heart$363,756
R01 · FY2005 · HL
AKAP Regulation of PKA Targeting in the Heart$319,444
R01 · FY2005 · AG
TARGETING OF PKA BY AKAP100 IN AGING AND FAILING HEARTS$317,903
R01 · FY2004 · AG
Beta-adrenergic Response in Cardiac Hypertrophy/Failure$273,720
R01 · FY2004 · HL
TARGETING OF PKA BY AKAP100 IN AGING AND FAILING HEARTS$208,588
R01 · FY2003 · AG
Beta-adrenergic Response in Cardiac Hypertrophy/Failure$140,572
R01 · FY2003 · HL
Beta-adrenergic Response in Cardiac Hypertrophy/Failure$131,428
R01 · FY2003 · HL
TARGETING OF PKA BY AKAP100 IN AGING AND FAILING HEARTS$84,740
R01 · FY2003 · AG
TARGETING OF PKA BY AKAP100 IN AGING AND FAILING HEARTS$284,785
R01 · FY2002 · AG
Beta-adrenergic Response in Cardiac Hypertrophy/Failure$272,000
R01 · FY2002 · HL
Beta-adrenergic Response in Cardiac Hypertrophy/Failure$281,835
R01 · FY2001 · HL
TARGETING OF PKA BY AKAP100 IN AGING AND FAILING HEARTS$276,488
R01 · FY2001 · AG
TARGETING OF PKA BY AKAP100 IN AGING AND FAILING HEARTS$289,481
R01 · FY2000 · AG
B ADRENERGIC RESPONSE IN CARDIAC HYPERTROPHY AND FAILURE$208,764
R01 · FY2000 · HL